U.S. National Library of MedicineNational Institutes of Health
Skip navigation
MedlinePlus Trusted Health Information for You MedlinePlus Trusted Health Information for You MedlinePlus Trusted Health Information for You
  FAQs Site Map About MedelinePlus Contact Us
español
Reuters Health Information Logo

Rise in cases of 'Valley Fever' seen in California

Printer-friendly version E-mail this page to a friend

Reuters Health

Thursday, February 12, 2009

NEW YORK (Reuters Health) - From 2000 to 2006, the rate of reported cases of coccidioidomycosis has increased steadily in California, according to a report released Thursday by the Centers for Disease Control and Prevention. In 2007, a slight drop in cases occurred, but the rate is still the highest it has been in the state since 1995.

Coccidioidomycosis, or "Valley Fever," is primarily encountered in southwestern states. It is caused by inhaling the spores of a fungus, Coccidioides immitis, released from the soil.

The disease usually affects the lungs and can have potentially severe consequences, especially in at-risk individuals such as the elderly, pregnant women, and people with compromised immune systems. Treatment usually includes rest and antifungal medications.

To cut their risk of coccidioidomycosis, at risk individuals are advised to limit their exposure to dusty air in endemic areas. The CDC says health care providers should consider a diagnosis of coccidioidomycosis in any patients who have recently lived or traveled in endemic areas and who present with flu-like illness, pneumonia, or evidence of widespread infection.

According to the new report, cases of coccidioidomycosis, a reportable disease in California, averaged about 2.5 per 100,000 population annually from 1995 to 2000. Between 2000 and 2006, however, the rate more than tripled, from 2.4 to 8.0 per 100,000 population.

Further analysis indicated that for each year from 2000 to 2006, both the number of coccidioidomycosis cases and the number of related hospitalizations climbed. During this period, coccidioidomycosis hospitalizations rose from 1.8 to 4.3 per 100,000 population.

In terms of reducing coccidioidomycosis cases, the report notes that "options for environmental control of coccidioidomycosis are limited, and no safe, effective vaccine for the disease exists currently. Developing such a vaccine appears to be the best option for preventing disease in those persons at risk for coccidioidomycosis."

SOURCE: Morbidity and Mortality Weekly Report, February 12, 2009.


Reuters Health

Copyright © 2009 Reuters Limited. All rights reserved. Republication or redistribution of Reuters content, including by framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. Reuters and the Reuters sphere logo are registered trademarks and trademarks of the Reuters group of companies around the world.


More News on this Date

Related MedlinePlus Pages: